Nantahala Capital Management - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Nantahala Capital Management ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2022$397,000
-78.1%
285,963
-14.6%
0.02%
-71.9%
Q4 2021$1,816,000
-8.4%
335,015
-3.5%
0.06%
+3.2%
Q3 2021$1,982,000
-6.2%
347,171
-4.5%
0.06%
+3.3%
Q2 2021$2,113,000
+6.2%
363,6220.0%0.06%
+3.4%
Q1 2021$1,989,000
+14.2%
363,6220.0%0.06%
+7.4%
Q4 2020$1,742,000363,6220.05%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 404,963$563,0000.48%
Cowen Prime Advisors LLC 332,197$462,0000.19%
ARMISTICE CAPITAL, LLC 834,054$1,159,0000.02%
Nantahala Capital Management 285,963$397,0000.02%
HighMark Wealth Management LLC 6,966$10,0000.01%
UBS Group AG 4,000$6,0000.00%
OSAIC HOLDINGS, INC. 13$00.00%
WELLS FARGO & COMPANY/MN 41$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 46,039$63,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders